低剂量秋水仙碱在冠心病患者中的疗效与安全性:随机试验的系统综述与荟萃分析
结果显示秋水仙碱使MACE风险降低25%(RR 0.75,95%CI 0.61-0.92;P=0.005),心肌梗死降低22%,卒中降低46%,冠状动脉血运重建降低23%,全因死亡无差异。
要点
- 低剂量秋水仙碱使冠心病患者MACE风险降低25%。
- 心肌梗死、卒中和冠状动脉血运重建风险分别降低22%、46%和23%。
- 全因死亡无差异,心血管死亡减少但非心血管死亡增加。
核心结论
- 低剂量秋水仙碱在广泛冠心病患者中降低MACE、心肌梗死、卒中和冠状动脉血运重建风险。
- 全因死亡率无差异,心血管死亡减少被非心血管死亡增加所抵消。
研究设计与样本
- 系统综述与荟萃分析,检索截至2020年9月1日发表的长期秋水仙碱治疗动脉粥样硬化患者的随机临床试验。
主要发现
- 主要终点发生在578例患者中,秋水仙碱使主要终点风险降低25%(RR 0.75,95%CI 0.61-0.92;P=0.005)。
- 心肌梗死风险降低22%(RR 0.78,95%CI 0.64-0.94;P=0.010)。
- 卒中风险降低46%(RR 0.54,95%CI 0.34-0.86;P=0.009)。
- 冠状动脉血运重建风险降低23%(RR 0.77,95%CI 0.66-0.90;P<0.001)。
- 全因死亡无差异(RR 1.08,95%CI 0.71-1.62;P=0.73),心血管死亡(RR 0.82,95%CI 0.55-1.23;P=0.34)与非心血管死亡(RR 1.38,95%CI 0.99-1.92;P=0.060)均无显著差异。
临床怎么用
- 对于近期心肌梗死或慢性冠心病患者,在指南指导治疗基础上可考虑加用低剂量秋水仙碱以降低MACE风险。
- 需关注非心血管死亡风险,个体化评估获益与风险。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIMS: Recent randomized trials demonstrated a benefit of low-dose colchicine added to guideline-based treatment in patients with recent myocardial infarction or chronic coronary disease. We performed a systematic review and meta-analysis to obtain best estimates of the effects of colchicine on major adverse cardiovascular events (MACE). METHODS AND RESULTS: We searched the literature for randomized clinical trials of long-term colchicine in patients with atherosclerosis published up to 1 September 2020. The primary efficacy endpoint was MACE, the composite of myocardial infarction, stroke, or cardiovascular death. We combined the results of five trials that included 11 816 patients. The primary endpoint occurred in 578 patients. Colchicine reduced the risk for the primary endpoint by 25% [relative risk (RR) 0.75, 95% confidence interval (CI) 0.61-0.92; P = 0.005], myocardial infarction by 22% (RR 0.78, 95% CI 0.64-0.94; P = 0.010), stroke by 46% (RR 0.54, 95% CI 0.34-0.86; P = 0.009), and coronary revascularization by 23% (RR 0.77, 95% CI 0.66-0.90; P < 0.001). We observed no difference in all-cause death (RR 1.08, 95% CI 0.71-1.62; P = 0.73), with a lower incidence of cardiovascular death (RR 0.82, 95% CI 0.55-1.23; P = 0.34) counterbalanced by a higher incidence of non-cardiovascular death (RR 1.38, 95% CI 0.99-1.92; P = 0.060). CONCLUSION: Our meta-analysis indicates that low-dose colchicine reduced the risk of MACE as well as that of myocardial infarction, stroke, and the need for coronary revascularization in a broad spectrum of patients with coronary disease. There was no difference in all-cause mortality and fewer cardiovascular deaths were counterbalanced by more non-cardiovascular deaths.
引用
- Fiolet ATL, Opstal TSJ, Mosterd A, et al. Efficacy and safety of low-dose colchicine in patients with coronary disease: a systematic review and meta-analysis of randomized trials. Eur Heart J. 2021. PMID: 33769515. doi:10.1093/eurheartj/ehab115
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。